Bioniche Pharma Launches Mefoxin(R) (cefoxitin injection) Premix IV Solution
LAKE FOREST, Ill., March 9 Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the launch of Mefoxin® (cefoxitin injection) frozen premix bags. The launch marks the company's first product offering to be supplied in a frozen premix bag presentation. Mefoxin (cefoxitin injection) is manufactured by Baxter Healthcare Corporation using Baxter's proprietary GALAXY container technology.
"Mefoxin® (cefoxitin injection) is another example of Bioniche Pharma's business strategy to grow the product portfolio with branded drugs, in addition to generic and niche market platforms," said George Zorich, President, US Operations for Bioniche Pharma. "Working with an established manufacturer for Mefoxin (cefoxitin injection) allows Bioniche Pharma to not only supply a much-needed product to our customers, but to also supply a generic therapy in a proprietary delivery system with Baxter's breadth of experience in the frozen premix bag market."
Bioniche Pharma will supply Mefoxin® (cefoxitin injection) in 1g and 2g frozen premix bags.
About Bioniche Pharma
Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, including anaesthesiology, orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma and prescribing information for its products can be found at www.bionichepharma.com.
Mefoxin® is a registered trademark of Bioniche Teoranta
Baxter and Galaxy are registered trademarks of Baxter International Inc.
SOURCE Bioniche Pharma
You May Also Like